355 related articles for article (PubMed ID: 21606426)
1. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer.
Neugut AI; Subar M; Wilde ET; Stratton S; Brouse CH; Hillyer GC; Grann VR; Hershman DL
J Clin Oncol; 2011 Jun; 29(18):2534-42. PubMed ID: 21606426
[TBL] [Abstract][Full Text] [Related]
2. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.
Hershman DL; Tsui J; Meyer J; Glied S; Hillyer GC; Wright JD; Neugut AI
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25349080
[TBL] [Abstract][Full Text] [Related]
3. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
[TBL] [Abstract][Full Text] [Related]
4. Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.
Neugut AI; Zhong X; Wright JD; Accordino M; Yang J; Hershman DL
JAMA Oncol; 2016 Oct; 2(10):1326-1332. PubMed ID: 27281650
[TBL] [Abstract][Full Text] [Related]
5. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
6. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Sedjo RL; Devine S
Breast Cancer Res Treat; 2011 Jan; 125(1):191-200. PubMed ID: 20495864
[TBL] [Abstract][Full Text] [Related]
7. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.
Biggers A; Shi Y; Charlson J; Smith EC; Smallwood AJ; Nattinger AB; Laud PW; Neuner JM
J Clin Oncol; 2016 Dec; 34(36):4398-4404. PubMed ID: 27998232
[TBL] [Abstract][Full Text] [Related]
8. The economic consequences of breast cancer adjuvant hormonal treatments.
Pezzin LE; O'Niel MB; Nattinger AB
J Gen Intern Med; 2009 Nov; 24 Suppl 2(Suppl 2):S446-50. PubMed ID: 19838848
[TBL] [Abstract][Full Text] [Related]
9. Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.
Hershman DL; Tsui J; Wright JD; Coromilas EJ; Tsai WY; Neugut AI
J Clin Oncol; 2015 Mar; 33(9):1053-9. PubMed ID: 25691670
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant hormonal therapy use among insured, low-income women with breast cancer.
Kimmick G; Anderson R; Camacho F; Bhosle M; Hwang W; Balkrishnan R
J Clin Oncol; 2009 Jul; 27(21):3445-51. PubMed ID: 19451445
[TBL] [Abstract][Full Text] [Related]
11. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
Ta JT; Sullivan SD; Tung A; Oliveri D; Gillard P; Devine B
J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
[No Abstract] [Full Text] [Related]
12. Adjuvant therapy use among Appalachian breast cancer survivors.
Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.
Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
J Manag Care Spec Pharm; 2016 Aug; 22(8):969-78. PubMed ID: 27459660
[TBL] [Abstract][Full Text] [Related]
14. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
15. Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers.
Zhang D; Carlson AM; Gleason PP; Schondelmeyer SW; Schommer JC; Dowd BE; Heaton AH
J Manag Care Pharm; 2007 Oct; 13(8):664-76. PubMed ID: 17970604
[TBL] [Abstract][Full Text] [Related]
16. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
[TBL] [Abstract][Full Text] [Related]
17. Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas.
Kim J; Rajan SS; Du XL; Franzini L; Giordano SH; Morgan RO
Breast Cancer Res Treat; 2018 Jun; 169(3):573-586. PubMed ID: 29423900
[TBL] [Abstract][Full Text] [Related]
18. Geographic Variations and the Associated Factors in Adherence to and Persistence with Adjuvant Hormonal Therapy for the Privately Insured women Aged 18-64 with Breast Cancer in Texas.
Kim J; Kim MS; Rajan SS; Du XL; Franzini L; Kim TG; Giordano SH; Morgan RO
Curr Oncol; 2023 Mar; 30(4):3800-3816. PubMed ID: 37185401
[TBL] [Abstract][Full Text] [Related]
19. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
Clark BE; Siracuse MV; Garis RI
Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Blanchette PS; Lam M; Richard L; Allen B; Shariff SZ; Vandenberg T; Pritchard KI; Chan KKW; Louie AV; Desautels D; Raphael J; Earle CC
Breast Cancer Res Treat; 2020 Jan; 179(1):217-227. PubMed ID: 31571072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
